Analyses of data from two large, independent US cohorts show that a home blood pressure (BP) threshold of 130/80 mm Hg corresponds to the same value in clinic BP for stage 1 hypertension diagnosis (based on the 2017 ACC/AHA* guidelines), thus lending support to the use of home BP cutoff of 130/80 mm Hg for diagnosis of hypertension.
Transdermal treatment appears to be the safest type of hormone replacement therapy (HRT) when assessing for the risk of venous thromboembolism (VTE), suggests a recent study. However, its use is much less frequent compared to oral preparations.
A recent study has shown that higher blood pressure (BP) during early pregnancy and greater decreases in BP from early to mid-pregnancy heightens the risk of small-for-gestational-age (SGA) birth, which suggests a range of risk for SGA birth according to BP beginning at early pregnancy.
Twice-daily treatment with icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, leads to a lower risk of major ischaemic events, including cardiovascular death, in patients with elevated triglyceride levels, according to the results of REDUCE-IT study.
The presence of frailty is associated with an elevated risk of subsequent incidence of cardiovascular disease, diabetes and bone disease among adults infected with HIV, a study has shown. Moreover, an increase in frailty over 48 weeks is tied to a greater risk of death.
Serum-based renal biomarkers, particularly Cystatin C, appear to be predictive of cardiovascular risk in type 2 diabetes mellitus (T2DM) patients with recent acute coronary syndrome (ACS), reports a new study.
Sex, renal failure and atrial fibrillation (AF) are most significantly associated with mortality at 3-year follow-up, whereas anticoagulation therapy, given mostly to AF patients, reduces the risk of bioprosthetic valve dysfunction (BVD) following transcatheter aortic valve replacement (TAVR), according to a recent study.
Combination therapy with ezetimibe/statin improved low-density lipoprotein (LDL) cholesterol levels and cardiovascular outcomes in patients with acute coronary syndrome (ACS), as stated in a 16-week one-centre, prospective, randomised, open-label clinical trial.
Prasugrel is superior than clopidogrel in the treatment of acute coronary syndrome (ACS) and ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) as presented in a study.
Earlier oral β blocker administration is substantially correlated with lower rates of left ventricular (LV) dysfunction and in-hospital mortality in acute coronary syndrome patients, according to a study.
The absence of the classical symptom of chest pain in patients with acute myocardial infarction (AMI) appears to be associated with more complications and higher short- and long-term mortality rates, particularly in younger and healthier patients, according to a study.